Use of mitochondrial iron chelators for treatment of chronic obstructive pulmonary disease
A method for treating one or more symptoms of COPD comprising administering to an in need of treatment a therapeutically effect amount of one or more mitochondrial iron chelators. The mitochondrial iron chelator can be deferiprone. Compostions comprising mitochondrial iron chelators suitable for administration are also disclosed.
1. A method for treating chronic obstructive pulmonary disease (COPD) comprising administering to an individual in need of treatment a therapeutically effective amount of a composition comprising a mitochondrial iron chelator wherein the mitochondrial chelator is deferiprone or pegylated derivatives thereof.
2. The method of claim 1 , wherein the composition is present in an aerosolized form.
3. The method of claim 1 , wherein the composition is administered via an oral route.
4. The method of claim 1 , wherein the composition is administered by inhalation.
5. The method of claim 1 , wherein the composition is administered via a cutaneous route.
6. The method of claim 1 , wherein the composition does not contain any other agent that has a therapeutic effect for COPD.
7. The method of claim 1 , wherein the composition does not contain any other iron chelator.
8. The method of claim 1 , wherein the composition further comprises an agent that has a therapeutic effect for COPD.
9. The method of claim 1 , wherein the individual is a smoker.
10. The method of claim 9 , wherein the individual has ceased smoking.
11. The method of claim 1 , wherein deferiprone is administered over a period of at least 3 weeks.
12. The method of claim 11 , wherein deferiprone is administered over a period of at least 4 weeks.